Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …

An elevated level of lipoprotein (a)[Lp (a)] is a genetically regulated, independent, causal
risk factor for cardiovascular disease. However, the extensive variability in Lp (a) levels …

Background Traditional classification systems of metabolic-associated fatty liver disease
(MAFLD) do not account for the high rate of extrahepatic complications. To create a new …

Dyslipidemia and cardiovascular complications are comorbidities of nonalcoholic fatty liver
disease (NAFLD), which ranges from simple steatosis to nonalcoholic steatohepatitis …

Abstract Lipoprotein (a)[Lp (a)] is made up of a low-density lipoprotein (LDL) particle and a
specific apolipoprotein (a). The blood concentration of Lp (a) is approximately 90 …

Abstract Background and Objectives It is well known that lipid abnormalities exist in the
context of non-alcoholic fatty liver disease (NAFLD). The association between lipoprotein …

Background and aims Lipoprotein (a)(Lp (a)) is a causal risk factor for cardiovascular
diseases and its levels are under strict genetic control. Therefore, it is hypothesized that the …

Background Progressive overloads of intrahepatic triglycerides are related to metabolic
dysregulation of multiple lipid and lipoprotein profiles, but whether similar dose effects are …

Although Lp (a) contributes to the development of cardiovascular disease in patients with
diabetes, few trials have investigated the benefits of reducing Lp (a) within this patient …

Background: Hepatic fibrosis reduces the serum level of lipoprotein (a)[Lp (a)] and may
affect its accuracy in cardiovascular disease prediction of metabolic-associated fatty liver …